There are a number of genetic diseases that are more prevalent among individuals of Jewish heritage than in the general population. These diseases are prevalent in all Ashkenazi, Sephardic, and Mizrahi Jewish populations. Notably, the microbiota plays a crucial role in many of these disease, including:
- Cystic fibrosis
- Familial hypercholesterolemia
- Parkinson’s disease
- Crohn’s disease
- Kaposi’s sarcoma
Our studies of social and ethnic factors that affect the human microbiota are dedicated to studying the particularity of the Jewish microbiota. The results of these studies will shed light on the role of these organisms in certain diseases that are more prevalent among the Jewish community, and may define the distinct composition of the microbiota that determines Jewish consciousness.
The Jewish population exhibits increased incidences of cystic fibrosis (CF) and, accordingly, an increased distribution of mutations in the CFTR gene. Specifically, the carrier frequency for common CF mutations is 30% higher among Ashkenazi Jews that in the general population. As such, the American College of Medical Genetics recommends that these individuals be offered carrier screening. We are delighted to present Mul-1867, a novel, first-in-class antimicrobial agent that can be used for treatment of cystic fibrosis patients suffering from pneumonia caused by drug-resistant bacterial strains. Mul-1867 was originally developed by the IHM core research group, and now is being developed by TGV-inhalonix (Hyperlink to the site).
IHM scientists discovered and are intensively studying new paradigms regarding the pathogenesis of cognitive diseases. Specifically, we have developed theories that shed light on the mechanisms by which the microbiota, particularly that of Jewish individuals, contributes to these diseases. Our primary research directions are described in the Age-related Cognitive Diseases section (Hyperlink to the раздел этого сайта)
Features of the microbiota that affect the development of Jewish consciousness
Gut microbiota are known to influence the development of the central nervous system and thereby influence brain function and behavior. IHM research is dedicated to characterizing the particularities of the Jewish microbiota that affect Jewish-specific brain function and make Jewish people Jewish.
Jewish microbiota-Jewish diseases
We propose that there is a particular component of the microbiome or a specific microbiota-host interaction that leads to the development of diseases that are more typical among the Jewish population. Research at the IHM is currently dedicated to addressing these questions to enable the treatment and prevention of “Jewish disorders”
READ MORE ABOUT THE JEWISH DISEASES
In vitro antimicrobial activity of a novel compound, Mul-1867, against clinically important bacteria.
Antimicrobial resistance and infection control (2015)
Antimicrobial activity of Mul-1867, a novel antimicrobial compound, against multidrug-resistant Pseudomonas aeruginosa.
Annals of Clinical Microbiology and Antimicrobials (2016)